Prednisolone Sodium Phosphate
Phase 3Small molecule
Prednisolone Sodium Phosphate is one of 9 small molecule programs targeting Wheezing. It is currently in Phase 3.
1
Indications
4
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Wheezing
#DrugCompanyPhaseTrials
1Flovent
PParatek Pharmaceuticals Inc
Approved
Spiriva
Boehringer IngelheimApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
Prednisolone Sodium Phosphate
UUniversity of Oulu
Phase 3
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Resveratrol
NNational Cancer Institute (NCI)
Preclinical
Inhaled Albuterol
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Otitis Media With Effusion1 trial
Wheezing1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Oulu